We applied the principle of synthetic lethality to discover a novel strategy for cancer treatment for patients with BRCA1 or ...

Drug resistance is a major clinical challenge in cancer treatment, underlying both tumour recurrence and patient mortality (Vasan et al, 2019). Yet when cancer cells develop resistance to a drug, ...

We transformed care for advanced prostate cancer, by validating inhibitors of androgen production as an effective cancer ...

PI3 kinase is a lipid signalling enzyme which plays a key role in the development and progression of many cancers as a result ...

We played a major role in revealing the biochemical steps of the RAS-RAF-MAP kinase pathway. We identified one of the major ...

Given the multifaceted and “double-edged sword” nature of radiation-induced immune activity, many clinical trials testing radio-immunotherapy in breast cancer – or indeed other cancer types such as ...

Established in 2013 as the Tumour Profiling Unit (TPU), and now rebranded as the ICR’s Genomics Facility, the Facility provides access to a range of cutting-edge techniques for genomic, transcriptomic ...

Metastatic cells are characterised as being highly invasive but weakly adhesive with rounded-amoeboid like features. These cells harbour high levels of cortical Myosin II activity and exert low ...

We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

The Royal Marsden NHS Foundation Trust is a world-leading specialist cancer hospital. The Institute of Cancer Research works in close partnership with The Royal Marsden to take the results of our ...

We provided the first conclusive evidence that the basic cause of cancer is damage to DNA. The discovery changed scientific opinion dramatically and marked a turning point for cancer research.

We led major clinical trials in radiotherapy and imaging which have changed standard clinical practice for cancer treatment.